Cormedix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewsWire • Thursday
CorMedix to Acquire Heron Assets, Adding Four Products and Targeting Up to $60 Million in SavingsMarketBeat • Tuesday
CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of CareGlobeNewsWire • Monday
CorMedix Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026GlobeNewsWire • 11/06/26
Earnings Preview: CorMedix (CRMD) Q3 Earnings Expected to DeclineZacks Investment Research • 11/04/26
CorMedix Therapeutics Provides Business Update, Reaffirms 2026 Total Revenue Guidance, and Reports Third Quarter Cash PositionGlobeNewsWire • 11/02/26
Cormedix Announces FDA Acceptance for Priority Review of Supplemental NDA for Rezzayo® (Rezafungin) for Prophylaxis of Invasive Fungal DiseasesGlobeNewsWire • 10/19/26
Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial OfficerPRNewsWire • 10/15/26
Wall Street Analysts Think CorMedix (CRMD) Could Surge 67.73%: Read This Before Placing a BetZacks Investment Research • 09/07/26
CorMedix Therapeutics to Participate in the Wells Fargo Healthcare ConferenceGlobeNewsWire • 09/01/26
Wall Street Analysts Believe CorMedix (CRMD) Could Rally 65.96%: Here's is How to TradeZacks Investment Research • 08/20/26
CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta GainsZacks Investment Research • 08/14/26
Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewsWire • 08/13/26
CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026GlobeNewsWire • 07/29/26